BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.

Is now the time to buy BMY? Find out in our full research report (it’s free).

StockStory’s Take

Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year. Despite these beats, the market responded negatively, reflecting concerns raised by management about continued macro and competitive pressures. CEO Chris Boerner pointed to strong demand across the company’s growth portfolio, especially in oncology and hematology, while also acknowledging regulatory wins and cost optimization initiatives. The quarter was further shaped by the launch of new therapies and an increased focus on reshaping the business for long-term growth.

Looking forward, Bristol-Myers Squibb’s updated guidance is driven by anticipated momentum in its growth portfolio, ongoing pipeline developments, and recent business development deals. Management highlighted a data-rich period ahead, with several key trial readouts and product launches expected to influence the company’s trajectory. CFO David Elkins cautioned that increased operating expenses are planned in the second half of the year to fund new investments. As Boerner noted, “We are investing in and prioritizing areas where we see the strongest potential for high-value assets,” signaling a continued focus on pipeline execution and portfolio optimization.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to robust demand in its growth brands, regulatory milestones, and the first impacts of portfolio reshaping through external partnerships and divestitures.

• Growth portfolio strength: Sales of oncology and hematology brands, especially Opdivo, Reblozyl, Breyanzi, and Camzyos, saw double-digit growth due to increased demand and new market launches. Management highlighted that these products are now over half of total business and contribute higher-than-average margins, supporting overall profitability.
• Regulatory and launch milestones: Major regulatory approvals in Europe for Opdivo and Qvantig, as well as streamlined U.S. cell therapy regulations, expanded patient access and simplified administration, which management expects will drive future utilization and efficiency gains.
• Productivity and cost initiatives: A $2 billion productivity program is underway, with $1 billion in planned savings for this year. Management emphasized that these funds are being reinvested into growth brands, R&D, and recent business development, while enabling margin improvement despite legacy product declines.
• Strategic partnerships and divestitures: The company entered a global collaboration with BioNTech for a new immuno-oncology therapy and licensed radiopharmaceutical assets from Philochem. Additionally, it spun out five immunology assets to a Bain Capital-backed company, allowing external development while retaining upside through milestones and equity stakes.
• New launches and adoption challenges: Recent launches like Cobenfy and Qvantig are progressing well, but management acknowledged challenges in changing entrenched prescribing behaviors. Efforts include physician education, expanded field force, and sequencing launches from community to hospital settings.

Drivers of Future Performance

Looking ahead, Bristol-Myers Squibb’s outlook is shaped by new clinical data, expanded product indications, and the execution of recently announced partnerships and cost initiatives.

• Pipeline milestones and trial readouts: The company expects a data-rich period over the next 12–24 months, with key late-stage readouts for milvexian (anticoagulant), admilparant (pulmonary fibrosis), and iberdomide (multiple myeloma). Success in these trials could validate new platforms and enable label expansions, which management believes are central to long-term growth.
• Operational investments and cost management: While operating expenses will rise due to increased R&D and partnership activity, productivity programs are designed to offset these costs. Management expects gross margins to improve over time as higher-margin growth brands become a larger share of the portfolio, though near-term pressures from legacy declines and new investments remain.
• Competitive and regulatory dynamics: The upcoming entry of new competitors, particularly in the myosin inhibitor space against Camzyos, and evolving U.S. policy on drug pricing and intellectual property, represent risks. Management is expanding access initiatives and direct-to-patient offerings to navigate these challenges and support future revenue streams.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team is monitoring (1) the pace and impact of major trial readouts, including for milvexian and Cobenfy Alzheimer’s indications, (2) the adoption rate of new launches like Qvantig and Cobenfy in both community and hospital settings, and (3) the realization of productivity savings and reinvestment into high-value brands. Evolving regulatory and competitive dynamics will also be important to track.

Bristol-Myers Squibb currently trades at $46.52, up from $46.01 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.